# A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema

> **NCT01315275** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 394 (actual)

## Conditions studied

- Visual Impairment
- Macular Edema

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01315275
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01315275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01315275, "A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01315275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*